Expressions of interest for patient participation in our Phase 3 clinical trial for EMD-RX5 are open as of today!

EMD-RX5 is aimed at treating the symptoms of psychological distress, such as anxiety, stress, depression, sleep disturbance and gastrointestinal upset that, at any one time, can affect up to 15% of the adult population.

Emyria has now qualified 8 clinical trial sites across Australia to support the pivotal Phase 3 trial.

“Qualified” sites have successfully passed extensive feasibility and suitability screens with an independent monitor. They are formally approved to participate in core trial activities such as patient recruitment, treatment dosing and clinical assessments.

If you’d like to express interest in participating in the trial, you can do so here: Programs – EMD-RX5 | Emerald Clinics